East End Medical Announces FDA Clearance Of Its SafeCross™ Transseptal RF Puncture And Steerable Balloon Introducer System

East End Medical, is a private medical device company committed to improving catheter-based cardiac procedures. Today the company announced it received U.S. Food and Drug Administration (FDA) clearance for the company’s SafeCrossTransseptal Radiofrequency (RF) Puncture & Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology and structural heart interventions requiring left atrial access.

“Transseptal crossing is required for a growing number of catheter-based procedures, including left atrial appendage closure, transcatheter mitral valve repair, and atrial fibrillation ablation. Current septal puncture devices require careful technique, controlled force, and can be challenging in certain anatomies or subsequent procedures,” commented Dr. Martin Leon, Professor of Medicine at Columbia University Medical Center (CUMC). “The SafeCross System can simplify left atrial access and improve safety during these procedures. I am excited for the meaningful impact this innovation will have for patients.”

The SafeCross System’s contrast-filled positioning balloon is ultra-visible under echocardiography and x-ray to facilitate precise puncture site selection, while the bi-directional steerable introducer sheath allows for safe maneuvering and perpendicular placement on the septum. The proprietary RF puncture dilator delivers electrical energy quickly and predictably to puncture the atrial septum. Designed to be compatible with commonly available electrosurgical generators, the SafeCross System can be easily adopted into clinical practice.

“With the rapid growth in left atrium procedures, physicians need a single device to precisely gain transseptal access at specific locations on the septum,” said Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Health System. “The SafeCross System, with the unique steerable balloon and RF puncture, was designed to provide physicians the control required to precisely select sites and puncture the septum in an efficient, safe, and reproducible manner.”

“We look forward to bringing this technology to the U.S. market with an initial limited release followed by expanded commercial efforts by the end of 2021,” stated Anthony Medigo, Chief Commercial Officer of East End Medical.

The SafeCross Transseptal RF Puncture & Steerable Balloon Introducer System will be on display at booth 1361 at the Heart Rhythm Society (HRS) meeting in Boston, MA on July 28-31, 2021.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.